Phase 3 RCT in 926 fit patients with untreated CLL (median follow-up 63.8 months): 5-year PFS was 81.3% with venetoclax-obinutuzumab-ibrutinib, 69.8% venetoclax-obinutuzumab, 57.4% venetoclax-rituximab, 50.7% chemoimmunotherapy; OS did not differ.
RCTn = 926
Fürstenau et al. Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial